+

WO2007014744A3 - Promedicament ctl - Google Patents

Promedicament ctl Download PDF

Info

Publication number
WO2007014744A3
WO2007014744A3 PCT/EP2006/007581 EP2006007581W WO2007014744A3 WO 2007014744 A3 WO2007014744 A3 WO 2007014744A3 EP 2006007581 W EP2006007581 W EP 2006007581W WO 2007014744 A3 WO2007014744 A3 WO 2007014744A3
Authority
WO
WIPO (PCT)
Prior art keywords
region
ctl
prodrug
family ligand
terminal
Prior art date
Application number
PCT/EP2006/007581
Other languages
English (en)
Other versions
WO2007014744A2 (fr
Inventor
Klaus Pfizenmaier
Harald Wajant
Iris Watermann
Jeannette Gerspach
Dafne Mueller
Original Assignee
Univ Stuttgart
Univ Wuerzburg J Maximilians
Klaus Pfizenmaier
Harald Wajant
Iris Watermann
Jeannette Gerspach
Dafne Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart, Univ Wuerzburg J Maximilians, Klaus Pfizenmaier, Harald Wajant, Iris Watermann, Jeannette Gerspach, Dafne Mueller filed Critical Univ Stuttgart
Publication of WO2007014744A2 publication Critical patent/WO2007014744A2/fr
Publication of WO2007014744A3 publication Critical patent/WO2007014744A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un polypeptide présentant de préférence des propriétés de cytokines antitumorales et/ou immunomodulatrices et pouvant être activé par maturation in vivo, ce polypeptide comprenant une région C-terminale possédant une activité biologique spécifique. Au niveau de la terminaison N de cette région C-terminale se trouvent une région inhibitrice, une région pourvue d'un site de maturation et une région capable de reconnaître sélectivement une macromolécule sur une surface cellulaire ou un constituant de la matrice extracellulaire.
PCT/EP2006/007581 2005-08-03 2006-07-31 Promedicament ctl WO2007014744A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005036542A DE102005036542A1 (de) 2005-08-03 2005-08-03 CTL-Prodrug
DE102005036542.6 2005-08-03

Publications (2)

Publication Number Publication Date
WO2007014744A2 WO2007014744A2 (fr) 2007-02-08
WO2007014744A3 true WO2007014744A3 (fr) 2007-04-12

Family

ID=37560705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007581 WO2007014744A2 (fr) 2005-08-03 2006-07-31 Promedicament ctl

Country Status (2)

Country Link
DE (1) DE102005036542A1 (fr)
WO (1) WO2007014744A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972350A1 (fr) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Système de double ciblage
EP2009022A1 (fr) * 2007-06-26 2008-12-31 Apogenix GmbH Ligands trimériques avec activité améliorée (tenascine)
EP2020249A1 (fr) 2007-08-01 2009-02-04 Boehringer Ingelheim Pharma GmbH & Co. KG Inhalateur
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CA2749339A1 (fr) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Compositions d'anticorps modifiees et leurs procedes de production et d'utilisation
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
MX2011010763A (es) 2009-04-17 2011-12-16 Basf Plant Science Co Gmbh Promotor de planta operable en endosperma y usos del mismo.
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
WO2012130471A1 (fr) * 2011-04-01 2012-10-04 Universität Stuttgart Polypeptides recombinés membres de la famille des ligands tnf ayant un domaine de liaison à l'anticorps et leurs utilisations
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
RS61870B1 (sr) 2014-11-14 2021-06-30 Hoffmann La Roche Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije
CN114751989B (zh) 2015-03-31 2025-03-14 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3231813A1 (fr) * 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Molécules de liaison d'antigène costimulantes trimères contenant un ligand de la famille du tnf
WO2018178074A1 (fr) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécules trimériques de liaison à l'antigène spécifiques pour récepteur de co-stimulation du tnf
WO2020260368A1 (fr) 2019-06-24 2020-12-30 Universität Stuttgart Agonistes de tnfr2 ayant une stabilité améliorée
WO2021097376A1 (fr) * 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Polypeptides de cytokine activables et leurs méthodes d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022833A1 (fr) * 2000-09-15 2002-03-21 Universität Stuttgart Proteine de fusion constituee d'un inhibiteur d'anticorps-cytokine-cytokine (selectokine) servant de promedicament specifique a la cible

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022833A1 (fr) * 2000-09-15 2002-03-21 Universität Stuttgart Proteine de fusion constituee d'un inhibiteur d'anticorps-cytokine-cytokine (selectokine) servant de promedicament specifique a la cible

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERSPACH J ET AL: "Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug.", CELL DEATH AND DIFFERENTIATION. FEB 2006, vol. 13, no. 2, February 2006 (2006-02-01), pages 273 - 284, XP002413275, ISSN: 1350-9047 *
SAMEL D ET AL: "Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 22 AUG 2003, vol. 278, no. 34, 22 August 2003 (2003-08-22), pages 32077 - 32082, XP002413361, ISSN: 0021-9258 *
WÜEST THOMAS ET AL: "TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.", ONCOGENE. 20 JUN 2002, vol. 21, no. 27, 20 June 2002 (2002-06-20), pages 4257 - 4265, XP002360030, ISSN: 0950-9232 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof

Also Published As

Publication number Publication date
WO2007014744A2 (fr) 2007-02-08
DE102005036542A1 (de) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007014744A3 (fr) Promedicament ctl
YU18903A (sh) Fuzioni proteini od inhibitora protivtela citokin- citokin (selektokin) kao ciljno specifični pro-lek
WO2008031045A3 (fr) Polypeptides aquarétiques et natriurétiques dépourvus d'activité vasodilatatoire
EP2447280A3 (fr) Analogues VEGF et leurs procédés d'utilisation
WO2010048308A3 (fr) Polypeptides natriurétiques
IL187188A0 (en) Improved human interferon molecules and their uses
WO2005081628A3 (fr) Peptides derives de la caseine et leurs utilisations therapeutiques
WO2008066752A3 (fr) Substances thérapeutiques à base de protéines modifiées ciblées sur des récepteurs de tyrosine kinases, dont l'igf-ir
WO2009086126A3 (fr) Polypeptides natriurétiques
WO2007131092A3 (fr) Récepteurs de lymphocytes t chimériques, matières associées et méthodes d'utilisation
EP3196213A3 (fr) Anticorps dirigés contre her-3 et leurs utilisations
EP2455461A3 (fr) Variantes de lipase pour utilisation pharmaceutique
WO2011146518A3 (fr) Peptide c pégylé
EP3597666A3 (fr) Compositions, utilisations et procédés pour le traitement de troubles métaboliques et de maladies
WO2006023766A3 (fr) Polynucleotides, polypeptides de p450 et leurs utilisations
EP1930424A4 (fr) Facteur d'induction d'apoptose atypique et procede d'induction d'apoptose par le même facteur
UA103215C2 (uk) Поліпептид з ксиланазною активністю
WO2008008482A3 (fr) Polypeptides de liaison à br3 modifiés
PH12014501363A1 (en) Anticancer fusion protein
EP1983003A3 (fr) Sites de phosphorylation à tyrosine et anticorps spécifiques
WO2009050277A3 (fr) Complexes de s100a12 résistants à l'edta (erac)
WO2006023356A3 (fr) Recepteur selectif vpac2 pour agonistes peptidiques
WO2006060728A3 (fr) Procedes et compositions impliquant des proteines lcrv
WO2005017188A3 (fr) Proteines de fusion a sequence de translocation membranaire et leurs procedes d'utilisation pour inhiber une reponse immune
WO2006083516A3 (fr) Polypeptide de cyanovirine-n modifie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06762913

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载